Scientific advisory board
CHAIR OF SCIENTIFIC ADVISORY BOARD
Jeff is Professor and Chair of Molecular and Experimental Medicine at The Scripps Research Institute. An expert on protein misfolding and amyloid-targeted drug discovery, he is a founder of FoldRx and an inventor of tafamidis, the first disease-modifying drug targeting an amyloidogenic protein. Tafamidis has been appoved in Europe (2011) and Japan (2013) and is currently under review by the FDA for the clinical treatment of transthyretin amyloidosis.
Usha is a Professor in the Department of Ophthalmology and Visual Sciences at Washington University. Usha is an expert on the role of crystallins in cataracts and the biochemical basis of human cataract formation.
Stan is Director of the Institute for Neurodegenerative Diseases and a Professor of Neurology at the University of California at San Francisco. Stan is an expert in protein misfolding pathology. His contributions have been recognized with numerous awards, including the Nobel Prize in Physiology or Medicine for his discovery of prions.
Richard is the former CEO and President of FoldRx, a company focused on protein misfolding diseases, which was acquired by Pfizer in 2010. Richard has deep expertise in medicinal chemistry.
Jason E. Gestwicki
Jason E. Gestwicki is a Co-Founder of Viewpoint Therapeutics. He earned a Ph.D. in Biochemistry from University of Wisconsin-Madison and completed postdoctoral studies at Stanford University. He is currently a Professor in the Department of Pharmaceutical Chemistry and the Institute for Neurodegenerative Disease (IND) at the University of California, San Francisco (UCSF). Dr. Gestwicki is an expert in the chemical biology of molecular chaperones, where his group seeks to identify new drug targets for protein misfolding diseases. He has published 160+ research articles and is an elected fellow of the American Association for the Advancement of Science and the Cell Stress Society International.